01388nas a2200457   4500000000100000000000100001000000100002008004100003653001100044653005400055653004400109653002300153653005000176653001100226653000900237653000900246653001600255653006000271653006500331653003300396653003200429653002000461653002300481653002200504653003200526653002100558653001100579653002800590653001700618653002500635100001200660700001100672700001600683700001400699700001400713245015600727250001500883300001100898490000700909020001400916       2024                            d10aHumans10a*Warfarin/adverse effects/administration & dosage10a*Sulfonylurea Compounds/adverse effects10a*Drug Interactions10a*Hypoglycemia/chemically induced/epidemiology10aFemale10aMale10aAged10aMiddle Aged10a*Anticoagulants/adverse effects/administration & dosage10a*Hypoglycemic Agents/adverse effects/administration & dosage10aPharmacoepidemiology/methods10aUnited Kingdom/epidemiology10aResearch Design10aDatabases, Factual10aAged, 80 and over10aProportional Hazards Models10apropensity score10acohort10adrug–drug interaction10ahypoglycemia10aprevalent new‐user1 aW. Wang1 aY. Cui1 aO. H. Y. Yu1 aS. Suissa1 aA. Douros00aThe Prevalent New-User Design to Study Drug-Drug Interactions: The Example of Sulfonylureas and Warfarin Interaction on the Risk of Severe Hypoglycemia  a2024/10/08  ae700140 v33  a1053-8569